| 臺大學術典藏 |
2022-02-14T06:28:45Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:43Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; YU-JEN FANG; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; YU-JEN FANG; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.‐Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Liu C.-J.; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; YU-JEN FANG; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T05:07:23Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; CHI-LING CHEN; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2022-01-25T03:24:58Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; Liu C.-J.; CHI-LING CHEN; Liu C.-H.; Yang H.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:32:01Z |
Patterns of managing chronic hepatitis B treatment-related drug resistance: A survey of physicians in Mainland China, South Korea, Taiwan, and Thailand
|
Chainuvati S.; Cheng J.; Hou J.L.; Hsu C.W.; Jia J.D.; Komolmit P.; Kwon S.Y.; Lee C.H.; Li H.; Li Y.; CHUN-JEN LIU; Neo B.L.; Peng C.Y.; Tanwandee T.; Wongcharatrawee S.; Wu J.C.; Yu M.L.; Zhang X.X. |
| 臺大學術典藏 |
2022-01-24T09:31:48Z |
Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients
|
Yuan Q.; Song L.-W.; CHUN-JEN LIU; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; Kao J.-H.; Chen D.-S.; Chen P.-J.; Xia N.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:48Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; CHUN-JEN LIU; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:33Z |
Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients
|
Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; Hsu S.-J.; Lai H.-C.; Su C.-W.; CHUN-JEN LIU; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:23Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; CHUN-JEN LIU; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV
|
CHUN-JEN LIU; Chuang W.-L.; Sheen I.-S.; Wang H.-Y.; Chen C.-Y.; Tseng K.-C.; Chang T.-T.; Massetto B.; Yang J.C.; Yun C.; Knox S.J.; Osinusi A.; Camus G.; Jiang D.; Brainard D.M.; McHutchison J.G.; Hu T.-H.; Hsu Y.-C.; Lo G.-H.; Chu C.-J.; Chen J.-J.; Peng C.-Y.; Chien R.-N.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Chien R.-N.; Kao J.-H.; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; CHUN-JEN LIU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; CHUN-JEN LIU; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; CHUN-JEN LIU; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:09Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:08Z |
2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:07Z |
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:05Z |
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:04Z |
Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH)
|
Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
|
Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; CHUN-JEN LIU; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; Hsu S.-J.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:59Z |
Sofosbuvir/Velpatasvir for Hepatitis?C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:57Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; CHUN-JEN LIU; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
|
Lin S.-R.; Yang T.-Y.; Peng C.-Y.; Lin Y.-Y.; Dai C.-Y.; Wang H.-Y.; Su T.-H.; Tseng T.-C.; Liu I.-J.; Cheng H.-R.; Shen Y.-C.; Wu F.-Y.; CHUN-JEN LIU; Chen D.-S.; Chen P.-J.; Yang H.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:55Z |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators |
| 臺大學術典藏 |
2022-01-24T09:30:55Z |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng P.-N.; Chen C.-Y.; Yu M.-L.; Lin C.-C.; Lin C.-Y.; Peng C.-Y.; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:30:54Z |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; Fang Y.-J.; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Kao J.-H.; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:51Z |
Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial
|
Cheng P.-N.; CHUN-JEN LIU; Chen C.-Y.; Tseng K.-C.; Lo C.-C.; Peng C.-Y.; Lin C.-L.; Chiu H.-C.; Chiu Y.-C.; Chen P.-J. |
| 國立成功大學 |
2022 |
Sulfonated GO coated carbon electrodes with cation-selective functions for enhanced capacitive deionization of saltwater
|
Cheng, H.-C.;Chen, P.-A.;Peng, C.-Y.;Liu, S.-H.;Wang, H.P. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection
|
Huang, Y.-S.;Tseng, S.-Y.;Chen, W.-W.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
|
Liu, C.J.;Sheen, I.S.;Chen, Chen C.Y.;Chuang, W.L.;Wang, H.Y.;Tseng, K.C.;Chang, T.T.;Yang, J.;Massetto, B.;Suri, V.;Camus, G.;Jiang, D.;Zhang, F.;Gaggar, A.;Hu, T.H.;Hsu, Y.C.;Lo, G.H.;Chu, Chu C.J.;Chen, J.J.;Peng, C.Y.;Chien, R.N.;Chen, P.J. |
| 國立成功大學 |
2022 |
The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan
|
Lin, C.-L.;Tai, C.-M.;Huang, J.-F.;Liu, C.-J.;Chen, H.-F.;Cheng, P.-N.;Chen, Chen C.-Y.;Peng, C.-Y.;Wang, C.-C.;Weng, S.-H.;Tseng, Tseng T.-C.;Kao, J.-H. |
